Details of the Drug

General Information of Drug (ID: DM70BU5)

Drug Name
Thalidomide
Synonyms
Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
Indication
Disease Entry ICD 11 Status REF
Adult T-cell leukemia/lymphoma N.A. Approved [1]
Advanced cancer 2A00-2F9Z Approved [1]
Complex regional pain syndrome type 1 N.A. Approved [1]
Hepatosplenic T-cell lymphoma N.A. Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Leukemia N.A. Approved [1]
MALT lymphoma N.A. Approved [1]
Multiple myeloma 2A83 Approved [2]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Pain MG30-MG3Z Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Prolymphocytic leukaemia 2A82.1 Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma N.A. Approved [1]
Splenic marginal zone lymphoma N.A. Approved [1]
Testicular lymphoma N.A. Approved [1]
Urinary bladder neoplasm N.A. Approved [1]
Waldenstrom macroglobulinemia 2A85.4 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
Colon cancer 2B90.Z Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Immunosuppressive Agents
Affected Organisms
Humans and other mammals
ATC Code
L04AX02: Thalidomide
L04AX: Other immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 258.23
Logarithm of the Partition Coefficient (xlogp) 0.3
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.4 mL/min/kg [5]
Elimination
0.5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.7 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 22.12781 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.4% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.95 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0525 mg/mL [4]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Deep vein thrombosis Not Available THBD OT8VHLKY [7]
Chemical Identifiers
Formula
C13H10N2O4
IUPAC Name
2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Canonical SMILES
C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
InChI
InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)
InChIKey
UEJJHQNACJXSKW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5426
ChEBI ID
CHEBI:74947
CAS Number
50-35-1
UNII
4Z8R6ORS6L
DrugBank ID
DB01041
TTD ID
D0U7GK
VARIDT ID
DR00461
INTEDE ID
DR1572
ACDINA ID
D00669
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Inhibitor [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [13]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [10]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [9]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Gene/Protein Processing [14]
Angiopoietin-1 receptor (TEK) OT78YN57 TIE2_HUMAN Gene/Protein Processing [15]
Angiopoietin-2 (ANGPT2) OTEQK65P ANGP2_HUMAN Gene/Protein Processing [16]
Annexin A2 (ANXA2) OTFNS0CC ANXA2_HUMAN Gene/Protein Processing [17]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [18]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [19]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Gene/Protein Processing [20]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Gene/Protein Processing [21]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Gene/Protein Processing [22]
C-X-C chemokine receptor type 1 (CXCR1) OT5512B2 CXCR1_HUMAN Gene/Protein Processing [23]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Adult T-cell leukemia/lymphoma
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 8.64E-01 -0.06 -0.16
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 6.01E-02 4.39E-01 1.83E+00
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 8.20E-01 3.19E-02 1.66E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 9.63E-01 1.10E-01 2.91E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 8.91E-01 -3.14E-02 -1.42E-01
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 1.23E-01 2.71E-01 8.39E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.47E-02 -1.30E+00 -1.39E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 5.67E-01 -4.03E-02 -2.13E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.00E-01 3.06E-02 1.84E-01
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 1.71E-02 7.25E-01 2.30E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 61 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 7.6021 9.074 5.5481 0.4162
JM1 CTRP2 6.9831 10.9027 4.3461 5.5161
697 CTRP2 6.2564 7.825 5.3241 2.6425
MOLP-8 CTRP2 6.6789 8.4599 5.3157 2.7716
SET-2 CTRP2 6.8566 9.8101 4.7879 3.9044
EJM CTRP2 6.8936 11.517 3.9795 7.1642
Hs 611.T CTRP2 6.9183 11.1743 4.1663 6.3555
SIG-M5 CTRP2 6.9346 8.0207 5.6625 0.5034
ST486 CTRP2 6.9616 9.4592 5.0275 2.7943
A4/Fukuda CTRP2 6.983 10.1844 4.6948 4.0965
A3/Kawakami CTRP2 7.0247 8.2402 5.6158 0.5786
MOLT-3 CTRP2 7.0628 9.5293 5.0599 2.5358
HEL 92.1.7 CTRP2 7.0792 9.5694 5.0516 2.5475
Granta-519 CTRP2 7.1454 13.0673 3.4029 9.105
Karpas-422 CTRP2 7.1779 9.0437 5.3508 1.3219
BL-70 CTRP2 7.1792 8.4118 5.6196 0.4643
OPM-2 CTRP2 7.1913 11.376 4.2634 5.5385
TF-1 CTRP2 7.2134 9.4647 5.1823 1.8927
L-428 CTRP2 7.2318 11.9938 3.9918 6.5797
DND-41 CTRP2 7.2718 9.4325 5.2309 1.6532
SUP-M2 CTRP2 7.2747 8.88 5.4731 0.8287
OCI-Ly3 CTRP2 7.3543 9.0878 5.4259 0.9146
Ci-1 CTRP2 7.3604 11.7273 4.2108 5.5032
SUP-HD1 CTRP2 7.3621 9.6027 5.2064 1.6486
HuNS1 CTRP2 7.3659 10.591 4.7555 3.3348
KO52 CTRP2 7.4383 8.8234 5.5738 0.4368
Namalwa CTRP2 7.4456 9.9879 5.0817 2.0099
HuT 78 CTRP2 7.5042 10.3661 4.9449 2.4486
OCI-AML-5 CTRP2 7.5055 9.4621 5.3448 1.0511
GA-10 CTRP2 7.5106 11.1431 4.5888 3.799
Mino CTRP2 7.546 8.875 5.6004 0.3233
LP-1 CTRP2 7.5633 10.3443 4.9895 2.22
RPMI-6666 CTRP2 7.6036 9.1894 5.5037 0.5246
Kasumi-2 CTRP2 7.6364 9.8025 5.2676 1.1916
HH [Human lymphoma] CTRP2 7.7044 10.115 5.1693 1.4549
RL CTRP2 7.7518 9.4478 5.4682 0.5342
JJN-3 CTRP2 7.7744 12.269 4.2288 4.8635
OCI-AML-3 CTRP2 7.8476 8.983 5.6784 0.1034
M-07e CTRP2 7.8533 10.4001 5.1252 1.472
JeKo-1 CTRP2 7.8611 9.6881 5.4225 0.5906
F-36P CTRP2 7.8628 10.7083 4.9968 1.8945
SEM CTRP2 7.8818 9.0088 5.6818 0.0938
CA46 CTRP2 7.9013 12.1495 4.3656 4.1723
MOTN-1 CTRP2 7.9034 9.5182 5.5063 0.3754
AML-193 CTRP2 7.9325 9.037 5.6901 0.0774
Kasumi-1 CTRP2 7.9491 9.61 5.4906 0.3898
OCI-M1 CTRP2 7.9758 9.4195 5.5718 0.2256
CMK CTRP2 7.9808 9.1157 5.6803 0.0801
NU-DHL-1 CTRP2 8.078 9.8239 5.4635 0.3945
HL-60 CTRP2 8.0973 9.2559 5.6736 0.0709
HD-MY-Z CTRP2 8.0982 9.8827 5.4497 0.4151
DB CTRP2 8.165 9.9475 5.4529 0.3821
OCI-Ly19 CTRP2 8.1845 10.3794 5.295 0.7385
EoL-1 CTRP2 8.1855 14.5742 3.4049 7.5261
Pfeiffer CTRP2 8.229 9.5959 5.604 0.1219
OCI-Ly10 CTRP2 8.2465 10.9589 5.0892 1.277
K-562 CTRP2 8.2858 14.4703 3.5211 6.9393
Daudi CTRP2 8.3429 9.8211 5.5671 0.1447
SUP-B15 CTRP2 8.3857 9.8295 5.5796 0.1224
Toledo CTRP2 8.6458 22.513 -0.1353 18.8604
KMS-20 CTRP2 12.7648 28.0963 -0.0109 13.0096
⏷ Show the Full List of 61 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 8.495 11.5614 4.9614 1.4815
OE19 CTRP2 6.716 7.8364 4.6814 0.1347
KYSE-30 CTRP2 7.6689 11.7569 4.4019 4.3244
TE-5 CTRP2 7.8165 12.4865 4.1534 5.1031
KYSE-450 CTRP2 7.8165 8.9934 5.6634 0.1282
EC-GI-10 CTRP2 7.9921 11.2142 4.8455 2.2961
OE33 CTRP2 8.0142 14.069 3.5312 7.2736
TE-11 CTRP2 8.0153 9.7268 5.4741 0.3976
KYSE-510 CTRP2 8.2138 9.8308 5.5152 0.2507
KYSE-150 CTRP2 8.2859 9.4449 5.675 0.0498
TE-14 CTRP2 8.5811 10.466 5.4277 0.2896
KYSE-520 CTRP2 8.6396 10.4817 5.4445 0.2472
OE21 CTRP2 8.6766 10.4785 5.4596 0.2162
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 7.5265 9.1783 4.5096 0.194
PK-45H CTRP2 7.3461 10.6369 4.7212 3.494
KP-2 CTRP2 7.5895 9.7612 5.2608 1.2523
PaTu 8988t CTRP2 7.6987 9.1325 5.5667 0.452
PSN1 CTRP2 7.8022 10.6328 4.9965 2.6621
Capan-1 CTRP2 7.8358 9.927 5.3149 0.8986
Panc 10.05 CTRP2 7.9474 10.134 5.2837 0.9136
Hs 766T CTRP2 8.0859 9.9502 5.4188 0.4881
DAN-G CTRP2 8.1093 9.5685 5.5694 0.1932
Panc 02.03 CTRP2 8.125 9.899 5.4546 0.5372
Panc 03.27 CTRP2 8.1584 9.5681 5.5879 0.2121
Panc 08.13 CTRP2 8.1913 10.1108 5.4022 0.4782
HuP-T3 CTRP2 8.228 15.5234 2.9781 9.1095
MIA PaCa-2 CTRP2 8.2669 9.7007 5.5814 0.1419
AsPC-1 CTRP2 8.3974 10.3265 5.4062 0.3879
Capan-2 CTRP2 8.5343 10.3038 5.4681 0.2383
Panc 04.03 CTRP2 8.5496 10.0488 5.5628 0.1142
SW1990 CTRP2 8.8112 10.5913 5.4696 0.1746
PaTu 8988s CTRP2 13.7055 32.5952 -1.5185 15.7278
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 32 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 8.4243 14.8002 3.4556 7.0062
Hs 839.T CTRP2 7.3111 8.5347 5.6305 0.3631
WM266-4 CTRP2 7.3903 8.4346 5.7012 0.1812
IGR-1 CTRP2 7.4105 9.4314 5.3082 1.2507
Hs 688(A).T CTRP2 7.4323 8.8248 5.5706 0.448
A2058 CTRP2 7.4372 8.5243 5.6869 0.2613
UACC-62 CTRP2 7.4475 8.6155 5.6573 0.2441
SK-MEL-2 CTRP2 7.5052 11.972 4.1919 7.2913
K029AX CTRP2 7.5392 8.942 5.5719 0.3907
HMCB CTRP2 7.6722 8.6898 5.7165 0.1233
WM115 CTRP2 7.7009 9.0656 5.5927 0.2778
WT2-iPS CTRP2 7.7153 9.2347 5.5349 0.5369
Hs 895.T CTRP2 7.7662 9.3846 5.4991 0.4524
COLO 792 CTRP2 7.8029 12.727 4.0305 7.5825
LOX-IMVI CTRP2 7.8737 10.1696 5.2331 1.1146
SK-MEL-3 CTRP2 7.8891 9.4317 5.5328 0.3263
RVH-421 CTRP2 7.9211 9.0118 5.6947 0.0746
IGR-37 CTRP2 7.9474 9.161 5.6528 0.1155
SK-MEL-24 CTRP2 7.9801 9.4292 5.57 0.2275
COLO 800 CTRP2 7.9946 10.1522 5.2986 0.8413
WM88 CTRP2 8.0003 11.9906 4.5 3.5454
UACC-257 CTRP2 8.0135 13.6086 3.7506 6.4161
A101D CTRP2 8.1513 9.386 5.6483 0.1187
IGR-39 CTRP2 8.1627 9.2734 5.6902 0.069
HT-144 CTRP2 8.1948 9.7534 5.5358 0.3036
Hs 294T CTRP2 8.2284 9.8446 5.5159 0.3346
Hs 940.T CTRP2 8.3604 10.458 5.3414 0.5386
MeWo CTRP2 8.4571 9.9351 5.5689 0.1224
COLO 829 CTRP2 8.538 10.1254 5.5322 0.1502
Malme-3M CTRP2 8.6371 12.0576 4.8247 1.7963
Hs 934.T CTRP2 8.7432 20.191 1.0747 15.0803
WM983B CTRP2 8.8399 10.8405 5.3924 0.2752
⏷ Show the Full List of 32 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 CTRP2 8.0415 11.0536 4.9431 2.6069
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-N-FI CTRP2 6.8798 10.9392 4.2535 6.0584
SK-N-SH CTRP2 7.5172 10.6751 4.811 4.0009
IMR-32 CTRP2 7.6636 15.3748 2.6502 11.2257
SK-N-BE(2) CTRP2 7.755 10.0461 5.2252 1.231
SK-N-DZ CTRP2 7.9808 14.1154 3.4864 7.4963
CHP-212 CTRP2 8.0276 9.7054 5.4872 0.3655
NH-6 CTRP2 8.0688 15.4407 2.9077 9.6131
KP-N-YN CTRP2 8.1123 10.7484 5.1103 1.312
SK-N-AS CTRP2 8.4462 10.0363 5.5298 0.1715
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-869 CTRP2 7.6677 9.5898 5.3722 0.8466
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TC71 CTRP2 7.2095 8.2325 5.703 0.2441
Hs 822.T CTRP2 7.2559 8.423 5.6498 0.3443
SK-N-MC CTRP2 7.4654 8.4026 5.7412 0.0998
MG-63 CTRP2 7.6611 10.7215 4.8762 2.5288
A-673 CTRP2 7.6962 9.0778 5.5862 0.2924
HOS CTRP2 8.1345 9.5488 5.5858 0.223
Hs 888.T CTRP2 8.1788 9.7737 5.5223 0.249
SK-ES-1 CTRP2 8.2046 9.9541 5.4665 0.3407
SaOS-2 CTRP2 8.24 15.0932 3.1932 8.2672
G-292 clone A141B1 CTRP2 8.3341 10.2925 5.3931 0.4383
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 53 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC1500 CTRP2 6.0157 6.9148 5.585 1.9869
BT-20 CTRP2 6.5814 8.0922 5.426 1.7271
UACC-812 CTRP2 7.1003 20.3105 -0.2289 21.7243
HCC38 CTRP2 7.3125 11.6406 4.2196 5.5373
HCC1428 CTRP2 7.6221 8.9781 5.5931 0.3072
HCC1419 CTRP2 7.7535 9.8262 5.3165 0.951
BT-474 CTRP2 7.815 9.324 5.5428 0.3348
BT-549 CTRP2 7.9314 15.1753 2.94 9.6957
MDA-MB-415 CTRP2 8.0907 15.8091 2.7444 10.2026
AU565 CTRP2 8.0952 13.7817 3.7224 6.4154
ZR-75-30 CTRP2 8.149 9.6592 5.5521 0.2094
Hs 578T CTRP2 8.2853 10.5571 5.2702 0.7465
HCC202 CTRP2 8.2904 11.0879 5.0572 1.3415
MDA-MB-468 CTRP2 8.3399 10.0053 5.5009 0.2385
SK-BR-3 CTRP2 8.3854 10.4383 5.3594 0.4884
EFM-192A CTRP2 8.3941 10.1164 5.4817 0.2544
MDA-MB-453 CTRP2 8.4298 9.9363 5.5587 0.1387
T-47D CTRP2 8.4581 11.4661 4.9828 1.4437
CAL-85-1 CTRP2 9.5737 17.2811 3.024 9.4271
MDA-MB-157 CTRP2 9.7197 26.3243 -1.2196 20.0508
Hs 578Bst CTRP2 11.6545 31.4779 -2.3548 20.0117
MDA-MB-361 CTRP2 12.6738 44.6355 -8.0437 27.8457
BT 271 CTRP2 6.8353 8.9456 5.1881 2.3285
BT 145 CTRP2 6.9684 8.9381 5.2759 1.822
BT 112 CTRP2 7.0792 9.4643 5.1007 2.3579
BT 498 CTRP2 7.1259 8.3986 5.5998 0.5546
BT 320 CTRP2 7.1471 8.5522 5.5465 0.6991
BT 482 CTRP2 7.1572 9.0839 5.3212 1.4473
BT 179 CTRP2 7.3039 8.895 5.4815 0.7806
BT 216 CTRP2 7.4207 11.8268 4.2042 5.4433
BT 328 CTRP2 7.4411 8.9207 5.5366 0.5311
BT 416 CTRP2 7.503 9.3966 5.3712 0.97
BT147 CTRP2 7.5242 11.0208 4.6548 3.5257
BT164 CTRP2 7.6208 8.8238 5.6497 0.1994
BT 131 CTRP2 7.6518 9.2979 5.4825 0.5523
BT 159 CTRP2 7.7285 9.0517 5.6089 0.2377
BT 504 CTRP2 7.7506 9.0261 5.6268 0.1994
BT 444 CTRP2 7.7808 9.0578 5.627 0.1905
BT 248 CTRP2 7.7816 9.7719 5.3523 0.8273
BT 286 CTRP2 7.8148 9.0532 5.6417 0.1589
BT 440 CTRP2 7.8215 10.159 5.2113 1.222
BT 422 CTRP2 7.857 9.5905 5.4588 0.5034
BT 224 CTRP2 7.8631 9.5471 5.4782 0.455
BT 232 CTRP2 7.8646 9.8442 5.362 0.7475
BT 330 CTRP2 7.8862 9.9859 5.3149 0.865
BT 172 CTRP2 7.9219 9.2054 5.6279 0.1533
BT 139 CTRP2 7.983 14.9235 3.0982 9.0067
BT 245 CTRP2 7.9896 9.7584 5.4513 0.4585
BT 340 CTRP2 8.0336 9.0944 5.7058 0.0518
BT 231 CTRP2 8.0561 14.0334 3.5765 7.0382
BT 333 CTRP2 8.1504 9.6729 5.5477 0.2159
BT 359 CTRP2 8.2169 9.7123 5.5588 0.1825
BT 228 CTRP2 11.4814 22.3307 1.8624 8.9239
⏷ Show the Full List of 53 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hs 683 CTRP2 7.3808 9.1558 5.4107 0.9418
DK-MG CTRP2 7.405 8.7308 5.5953 0.4009
CCF-STTG1 CTRP2 7.4735 8.8114 5.5939 0.3706
D283 Med CTRP2 7.5684 8.992 5.5652 0.3924
Becker CTRP2 7.6468 10.0674 5.1591 1.5404
GMS-10 CTRP2 7.6531 8.7632 5.6838 0.1863
U-251MG CTRP2 7.8104 9.7561 5.3723 0.7528
A-172 CTRP2 7.8585 10.2434 5.1945 1.2458
8-MG-BA CTRP2 7.9339 10.2349 5.2357 1.4491
YKG-1 CTRP2 7.949 9.6008 5.494 0.3826
M059K CTRP2 7.9767 9.0731 5.6933 0.0934
U-118MG CTRP2 8.0328 9.4316 5.5893 0.1826
YH-13 CTRP2 8.0341 10.7864 5.0543 2.1141
GOS-3 CTRP2 8.0742 10.1207 5.3475 0.9067
SF539 CTRP2 8.1518 16.1305 2.6314 10.5373
SW1783 CTRP2 8.1656 15.0662 3.1555 8.5188
TM-31 CTRP2 8.1946 9.765 5.5316 0.3128
KNS-42 CTRP2 8.2734 10.0022 5.4762 0.2997
SF268 CTRP2 8.5089 12.6888 4.4817 3.0656
42-MG-BA CTRP2 8.5756 16.8018 2.601 10.0267
T98G CTRP2 8.6193 10.2565 5.5162 0.1543
SNB-75 CTRP2 8.8457 13.687 4.228 3.6244
KG-1-C CTRP2 8.8692 20.3062 1.1086 14.7792
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
EN CTRP2 6.3506 7.5449 5.5315 1.632
JHUEM-3 CTRP2 7.4462 14.0927 3.1203 9.7469
MFE-319 CTRP2 7.5155 8.955 5.5565 0.599
MFE-296 CTRP2 7.5671 10.6474 4.854 2.7161
JHUEM-7 CTRP2 7.5798 10.1176 5.1003 1.8067
AN3-CA CTRP2 7.6488 10.5447 4.9489 2.2767
JHUEM-1 CTRP2 7.7209 8.5654 5.7755 0.0325
ESS-1 CTRP2 7.9598 10.4872 5.1432 1.8097
HEC-1-A CTRP2 8.1172 9.8454 5.4715 0.3629
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RCC10RGB CTRP2 7.5329 12.5772 3.9199 6.4215
TUHR14TKB CTRP2 7.6856 10.2053 5.12 3.5087
UO-31 CTRP2 7.748 10.817 4.8838 2.408
KMRC-1 CTRP2 7.7716 9.5191 5.449 0.572
Caki-2 CTRP2 7.7816 11.346 4.6634 4.336
VMRC-RCZ CTRP2 7.8066 9.6829 5.3999 0.9273
CAL-54 CTRP2 7.8751 9.9227 5.3353 0.8148
A-498 CTRP2 8.2159 9.6537 5.5791 0.2114
786-O CTRP2 8.312 10.0389 5.478 0.2845
KMRC-3 CTRP2 8.3686 14.4077 3.6048 6.5069
ACHN CTRP2 8.3775 10.0449 5.501 0.2284
Caki-1 CTRP2 9.263 15.3387 3.7266 6.6788
KMRC-2 CTRP2 9.4116 15.7669 3.62 5.2021
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-C1 CTRP2 6.9641 10.0389 4.7519 3.8931
HCC-56 CTRP2 7.0787 8.2668 5.6311 0.4961
SNU-C4 CTRP2 7.212 8.6923 5.5204 0.7304
SW948 CTRP2 7.4694 8.8342 5.5833 0.3975
NCI-H716 CTRP2 7.6863 10.6778 4.9108 2.3755
HCT 8 CTRP2 7.8216 9.1108 5.6237 0.1846
RCM-1 [Human ESC] CTRP2 7.8222 9.4516 5.4974 0.4301
HCT 15 CTRP2 7.8914 9.2037 5.617 0.1767
COLO 678 CTRP2 8.0169 16.3345 2.4363 11.4741
GP2d CTRP2 8.0356 14.13 3.5165 7.3012
SNU-503 CTRP2 8.071 9.9699 5.4049 0.527
SW1417 CTRP2 8.0727 10.1419 5.3385 0.6888
LS1034 CTRP2 8.0732 9.9814 5.4014 0.5341
NCI-H747 CTRP2 8.1367 11.1205 4.9649 1.7561
C2BBe1 CTRP2 8.361 10.2946 5.4034 0.407
COLO 320 CTRP2 8.7272 11.668 5.0294 1.1271
T84 CTRP2 8.9727 11.2135 5.309 0.3742
SNU-1033 CTRP2 10.3084 55.7349 -15.3429 36.2797
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-475 CTRP2 5.8381 6.4414 5.6557 2.8371
JHH-6 CTRP2 6.7195 14.0242 2.6022 17.1337
HuH-1 CTRP2 7.4943 9.1512 5.4685 0.9348
JHH-2 CTRP2 7.8609 12.3501 4.2463 6.355
SNU-387 CTRP2 7.8914 12.0402 4.4104 4.0132
SK-HEP-1 CTRP2 8.0486 9.2534 5.6573 0.0933
SNU-423 CTRP2 8.1112 9.8403 5.471 0.3661
PLC/PRF/5 CTRP2 8.1276 9.6459 5.5487 0.3006
JHH-1 CTRP2 8.2046 9.6691 5.5695 0.2324
SNU-449 CTRP2 8.527 10.7344 5.3065 0.5429
HLF CTRP2 8.6072 10.2569 5.5117 0.2209
JHH-4 CTRP2 8.7117 10.3393 5.5209 0.133
JHH-5 CTRP2 8.8045 10.5375 5.4859 0.1564
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 61 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COR-L88 CTRP2 6.1154 9.9219 4.1645 7.764
NCI-H1105 CTRP2 6.1659 9.2121 4.5606 8.1845
NCI-H1341 CTRP2 6.2672 7.9655 5.2626 2.8806
NCI-H2141 CTRP2 6.4151 16.4051 1.1696 18.7749
NCI-H1568 CTRP2 6.6484 8.4142 5.3172 2.0687
NCI-H1092 CTRP2 6.6862 11.739 3.7127 8.6131
NCI-H2196 CTRP2 6.7126 8.6716 5.2373 2.299
SK-MES-1 CTRP2 6.8446 9.72 4.8232 3.7789
COLO 668 CTRP2 6.8734 9.8304 4.7898 3.8719
HCC4006 CTRP2 6.9161 9.7658 4.8505 3.5646
LC-1/sq-SF CTRP2 7.0705 9.8067 4.9343 3.0176
LK2 CTRP2 7.1161 8.081 5.7213 0.2444
NCI-H1793 CTRP2 7.2313 9.8645 5.0096 2.5219
NCI-H810 CTRP2 7.2598 9.6792 5.1122 2.101
COR-L51 CTRP2 7.2976 11.5342 4.2607 5.3931
Lu-65 CTRP2 7.3758 12.4559 3.869 6.8585
HOP-62 CTRP2 7.4158 11.3591 4.4247 4.5703
T3M-10 CTRP2 7.4238 11.2943 4.4608 4.4162
NCI-H2029 CTRP2 7.4481 9.5579 5.2735 1.3335
VMRC-LCD CTRP2 7.4601 9.0937 5.4757 0.6877
COR-L95 CTRP2 7.4659 9.3601 5.3677 1.01
HCC2935 CTRP2 7.5147 10.7159 4.7906 3.0165
NCI-H23 CTRP2 7.5387 11.1749 4.5919 3.7514
NCI-H2171 CTRP2 7.5403 9.6768 5.2713 1.2599
KNS-62 CTRP2 7.5559 9.5176 5.347 1.0045
DV-90 CTRP2 7.5643 10.1615 5.072 1.9219
NCI-H838 CTRP2 7.5811 8.9422 5.5896 0.3316
NCI-H1339 CTRP2 7.6127 9.5797 5.3494 1.3004
NCI-H520 CTRP2 7.673 9.7345 5.3148 1.0146
ChaGo-K-1 CTRP2 7.6896 11.0282 4.7535 2.9523
IA-LM CTRP2 7.8402 9.4945 5.4886 0.4418
RERF-LC-Ad2 CTRP2 7.8553 10.0157 5.2879 0.9638
NCI-H1563 CTRP2 7.8877 9.2539 5.5976 0.2083
NCI-H1703 CTRP2 7.9151 9.9248 5.3531 0.7413
DMS 53 CTRP2 7.9265 10.0568 5.3052 0.8662
NCI-H2170 CTRP2 7.9908 10.8767 4.9927 1.7915
NCI-H647 CTRP2 8.0596 15.2346 3.0011 9.2682
RERF-LC-MS CTRP2 8.078 9.8522 5.4528 0.4169
NCI-H2110 CTRP2 8.0884 10.7649 5.0913 1.3894
NCI-H1623 CTRP2 8.1355 10.5978 5.1841 1.0742
DMS 273 CTRP2 8.1606 10.0784 5.4016 0.6723
DMS 114 CTRP2 8.1883 16.104 2.6699 10.3376
NCI-H1693 CTRP2 8.1897 15.6006 2.9145 9.4082
Calu-1 CTRP2 8.2683 15.1641 3.1784 8.2843
NCI-H1944 CTRP2 8.2736 10.2859 5.3703 0.5129
HCC1438 CTRP2 8.2808 17.6386 1.9889 12.694
DMS 454 CTRP2 8.2911 16.0527 2.7663 9.8216
NCI-H1915 CTRP2 8.3178 9.8326 5.5539 0.1668
LUDLU-1 CTRP2 8.3341 9.992 5.5034 0.2361
NCI-H322 CTRP2 8.3428 13.4569 4.0335 6.6246
NCI-H1694 CTRP2 8.3634 9.7769 5.5898 0.115
NCI-H2342 CTRP2 8.4574 10.2295 5.4654 0.2631
NCI-H841 CTRP2 8.5127 9.8492 5.6175 0.0695
NCI-H2081 CTRP2 8.5175 10.9589 5.2158 0.759
NCI-H1395 CTRP2 8.5625 11.2628 5.1158 0.9924
NCI-H1869 CTRP2 8.7037 11.1672 5.2161 0.6664
COR-L105 CTRP2 9.1742 15.9314 3.4019 8.3377
EKVX CTRP2 9.9079 21.9398 1.0403 13.498
NCI-H522 CTRP2 9.9565 24.0898 0.0374 16.42
NCI-H1651 CTRP2 13.4048 37.6953 -4.1464 21.3968
Hs 888.Lu CTRP2 7.8977 11.1541 4.8188 2.4862
⏷ Show the Full List of 61 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 7.4035 8.4067 5.7164 0.1512
P-STS CTRP2 7.5906 9.349 5.4337 0.7212
SYO-1 CTRP2 7.7503 10.8036 4.8912 2.3788
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 7.967 9.7008 5.4636 0.4409
Aska-SS CTRP2 8.4323 9.7973 5.6071 0.0877
TE 441.T CTRP2 6.1664 7.3651 5.4828 2.9113
Hs 729.T CTRP2 6.286 8.711 4.9067 4.3357
BT-12 CTRP2 7.1769 8.1602 5.7167 0.2283
SW982 CTRP2 7.4203 9.7375 5.1793 1.6862
Tm87-16 CTRP2 7.5613 9.0052 5.557 0.415
HT-1080 CTRP2 7.5718 8.9481 5.5835 0.3492
KYM-1 CTRP2 7.618 9.2507 5.4859 0.5625
TE 617.T CTRP2 7.7064 9.4 5.4667 0.5626
BT-16 CTRP2 7.753 8.9489 5.6555 0.1537
SK-UT-1 CTRP2 7.8917 9.9864 5.3173 0.8546
MES-SA CTRP2 7.9446 9.2295 5.6278 0.2022
SK-LMS-1 CTRP2 8.0045 13.6403 3.7296 8.7593
G-401 CTRP2 8.0682 10.5165 5.1849 1.1186
TTC-709 CTRP2 8.1166 10.0094 5.4093 0.4957
GCT CTRP2 8.6886 15.8281 3.1418 7.8472
G-402 CTRP2 8.8826 12.0844 4.934 1.7632
A-204 CTRP2 9.0414 11.2017 5.3398 0.3036
RD CTRP2 9.0758 12.0829 5.023 0.9445
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 7.9985 9.6666 5.4898 0.3716
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 8.1525 11.5089 4.8046 2.2835
COV644 CTRP2 7.4445 11.0801 4.5759 3.9351
OV56 CTRP2 7.4471 8.3456 5.7544 0.1184
TOV-21G CTRP2 7.5259 8.755 5.6372 0.3474
COV362 CTRP2 7.5994 10.4998 4.9404 2.3606
OAW42 CTRP2 7.6281 8.6061 5.7296 0.1136
OV7 CTRP2 7.67 9.3539 5.4686 0.788
OVCAR-5 CTRP2 7.8314 11.7663 4.5 3.7436
JHOS-2 CTRP2 7.9498 9.5494 5.5137 0.3417
TOV-112D CTRP2 7.9691 9.6678 5.4771 0.4104
EFO-21 CTRP2 8.004 9.5319 5.5419 0.2687
OC 314 CTRP2 8.0094 9.4976 5.5565 0.2414
OAW28 CTRP2 8.1419 13.027 4.1079 6.5838
OV-90 CTRP2 8.155 10.6286 5.1809 1.0703
EFO-27 CTRP2 8.1571 9.8268 5.4944 0.3047
JHOM-1 CTRP2 8.307 16.7449 2.4423 11.0081
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JL-1 CTRP2 7.9758 10.2431 5.2527 0.9838
IST-Mes1 CTRP2 8.3353 9.9817 5.5076 0.3127
MPP 89 CTRP2 8.3631 10.183 5.4455 0.3259
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP2 7.0872 10.1312 4.7911 3.5624
VCaP CTRP2 7.4987 13.7612 3.3207 8.8698
LNCaP clone FGC CTRP2 7.8151 10.911 4.8803 2.3508
DU145 CTRP2 8.1502 11.656 4.7384 2.517
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 CTRP2 6.7333 9.0582 5.0658 4.0332
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuG1-N CTRP2 7.1074 11.1105 4.3332 5.3799
SNU-16 CTRP2 7.4616 8.9811 5.5219 0.5583
Hs 746.T CTRP2 7.6914 9.111 5.5718 0.4414
SNU-1 CTRP2 7.7485 10.1539 5.1758 1.3954
SH-10-TC CTRP2 7.9341 9.2842 5.6045 0.1848
HGC-27 CTRP2 8.0558 10.0351 5.3729 0.6113
LMSU CTRP2 8.0883 12.64 4.2544 4.3693
KATO III CTRP2 8.4501 10.103 5.5078 0.2006
MKN74 CTRP2 8.7629 21.6036 0.3977 17.1446
IM95 CTRP2 8.768 10.3595 5.5339 0.111
SNU-601 CTRP2 8.9193 10.4832 5.5448 0.0828
MKN7 CTRP2 10.852 21.7009 1.7679 9.9506
KE-39 CTRP2 12.2284 22.171 2.3649 6.5693
SNU-216 CTRP2 13.3865 28.2838 0.2843 11.5318
SNU-685 CTRP2 7.7058 9.3287 5.4945 0.4934
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
FTC-238 CTRP2 7.2001 9.1367 5.322 1.9102
TT2609-C02 CTRP2 8.028 11.4183 4.7751 3.4179
SW579 CTRP2 8.2508 9.4055 5.6762 0.0522
FTC-133 CTRP2 8.4875 9.9171 5.5858 0.1003
Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-2 CTRP2 7.1565 9.459 5.1508 2.8282
BICR 18 CTRP2 7.348 9.3739 5.2995 1.3373
PE/CA-PJ15 CTRP2 7.4044 10.7098 4.7243 3.407
BICR 22 CTRP2 7.4108 8.8306 5.5586 0.4906
PE/CA-PJ49 CTRP2 7.4317 9.4793 5.2988 1.2635
PE/CA-PJ34 (clone C12) CTRP2 7.4498 9.2894 5.3894 0.9543
BICR 56 CTRP2 7.4595 10.0392 5.0667 2.0496
FaDu CTRP2 7.6567 9.5479 5.3841 0.8196
BICR 31 CTRP2 7.6898 11.4867 4.5417 3.7563
BICR 6 CTRP2 7.6995 9.565 5.3975 0.7529
SCC-9 CTRP2 7.7354 14.2882 3.2326 11.7901
SCC-4 CTRP2 7.7688 10.0989 5.2098 1.2687
CAL-33 CTRP2 7.7734 9.7825 5.3441 0.8563
PE/CA-PJ41 (clone D2) CTRP2 7.8737 10.3922 5.1392 1.4096
CAL-27 CTRP2 8.1367 9.4187 5.6319 0.1448
BICR 16 CTRP2 8.404 10.05 5.5092 0.2095
⏷ Show the Full List of 16 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
647V CTRP2 7.7286 9.1627 5.5677 0.4329
KMBC-2 CTRP2 7.8862 10.8283 4.9569 2.0098
UM-UC-1 CTRP2 7.9524 10.6047 5.0894 1.5053
U-BLC1 CTRP2 7.9856 9.6044 5.5078 0.34
HT-1197 CTRP2 8.0012 9.4099 5.585 0.1972
BC-3C CTRP2 8.0427 9.4334 5.5924 0.2395
SCaBER CTRP2 8.2505 9.6894 5.5793 0.2014
J82 CTRP2 8.3308 10.9315 5.1412 1.067
T24 CTRP2 11.9828 21.1386 2.6829 7.5134
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HeLa CTRP2 7.4314 8.313 5.76 0.083

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Thalidomide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Carfilzomib DM48K0X Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Carfilzomib. Multiple myeloma [2A83] [24]
Panobinostat DM58WKG Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Panobinostat. Multiple myeloma [2A83] [25]
Elotuzumab DMEYHG9 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Elotuzumab. Multiple myeloma [2A83] [24]
Melphalan DMOLNHF Major Additive thrombogenic effects by the combination of Thalidomide and Melphalan. Multiple myeloma [2A83] [26]
Coadministration of a Drug Treating the Disease Different from Thalidomide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Ivosidenib. Acute myeloid leukaemia [2A60] [25]
Midostaurin DMI6E0R Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Midostaurin. Acute myeloid leukaemia [2A60] [25]
Idarubicin DMM0XGL Major Additive thrombogenic effects by the combination of Thalidomide and Idarubicin. Acute myeloid leukaemia [2A60] [26]
Arn-509 DMT81LZ Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Arn-509. Acute myeloid leukaemia [2A60] [25]
Gilteritinib DMTI0ZO Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Gilteritinib. Acute myeloid leukaemia [2A60] [25]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Thalidomide and Oliceridine. Acute pain [MG31] [27]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Thalidomide and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [28]
Ivabradine DM0L594 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Ivabradine. Angina pectoris [BA40] [25]
Bepridil DM0RKS4 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Bepridil. Angina pectoris [BA40] [25]
Dronedarone DMA8FS5 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Dronedarone. Angina pectoris [BA40] [25]
Nifedipine DMSVOZT Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Nifedipine. Angina pectoris [BA40] [25]
Bedaquiline DM3906J Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [25]
Chlormezanone DMTWUXR Moderate Additive CNS depression effects by the combination of Thalidomide and Chlormezanone. Anxiety disorder [6B00-6B0Z] [28]
Cilostazol DMZMSCT Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Cilostazol. Arterial occlusive disease [BD40] [25]
Posaconazole DMUL5EW Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Posaconazole. Aspergillosis [1F20] [25]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Thalidomide and Roflumilast. Asthma [CA23] [27]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [25]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Thalidomide and Desipramine. Attention deficit hyperactivity disorder [6A05] [29]
Ofloxacin DM0VQN3 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Ofloxacin. Bacterial infection [1A00-1C4Z] [25]
Clarithromycin DM4M1SG Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Clarithromycin. Bacterial infection [1A00-1C4Z] [25]
Sparfloxacin DMB4HCT Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [25]
Gemifloxacin DMHT34O Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [25]
Norfloxacin DMIZ6W2 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Norfloxacin. Bacterial infection [1A00-1C4Z] [25]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Levofloxacin. Bacterial infection [1A00-1C4Z] [25]
Retigabine DMGNYIH Moderate Additive CNS depression effects by the combination of Thalidomide and Retigabine. Behcet disease [4A62] [27]
Cariprazine DMJYDVK Moderate Additive CNS depression effects by the combination of Thalidomide and Cariprazine. Bipolar disorder [6A60] [29]
Lomustine DMMWSUL Major Additive thrombogenic effects by the combination of Thalidomide and Lomustine. Brain cancer [2A00] [26]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Eribulin. Breast cancer [2C60-2C6Y] [25]
Ixabepilone DM2OZ3G Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Ixabepilone. Breast cancer [2C60-2C6Y] [24]
Thiotepa DMIZKOP Major Additive thrombogenic effects by the combination of Thalidomide and Thiotepa. Breast cancer [2C60-2C6Y] [26]
Anastrozole DMNP60F Major Additive thrombogenic effects by the combination of Thalidomide and Anastrozole. Breast cancer [2C60-2C6Y] [26]
Cabazitaxel DMPAZHC Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Cabazitaxel. Breast cancer [2C60-2C6Y] [24]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [24]
Atorvastatin DMF28YC Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [24]
PF-04449913 DMSB068 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [25]
Dihydrocodeine DMB0FWL Moderate Additive CNS depression effects by the combination of Thalidomide and Dihydrocodeine. Chronic pain [MG30] [28]
Levetiracetam DMTGDN8 Moderate Additive CNS depression effects by the combination of Thalidomide and Levetiracetam. Chronic pain [MG30] [29]
Necitumumab DMKOJSN Major Additive thrombogenic effects by the combination of Thalidomide and Necitumumab. Colorectal cancer [2B91] [30]
Capecitabine DMTS85L Major Additive thrombogenic effects by the combination of Thalidomide and Capecitabine. Colorectal cancer [2B91] [26]
Halothane DM80OZ5 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Halothane. Corneal disease [9A76-9A78] [25]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Sevoflurane. Corneal disease [9A76-9A78] [25]
Ketamine DMT5HA4 Moderate Additive CNS depression effects by the combination of Thalidomide and Ketamine. Corneal disease [9A76-9A78] [29]
Probucol DMVZQ2M Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Probucol. Coronary atherosclerosis [BA80] [25]
Chlophedianol DMXGJEI Moderate Additive CNS depression effects by the combination of Thalidomide and Chlophedianol. Cough [MD12] [28]
Pasireotide DMHM7JS Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Pasireotide. Cushing syndrome [5A70] [25]
Osilodrostat DMIJC9X Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Osilodrostat. Cushing syndrome [5A70] [25]
Sertraline DM0FB1J Moderate Additive CNS depression effects by the combination of Thalidomide and Sertraline. Depression [6A70-6A7Z] [29]
Nefazodone DM4ZS8M Moderate Additive CNS depression effects by the combination of Thalidomide and Nefazodone. Depression [6A70-6A7Z] [29]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Thalidomide and Isocarboxazid. Depression [6A70-6A7Z] [29]
Escitalopram DMFK9HG Moderate Additive CNS depression effects by the combination of Thalidomide and Escitalopram. Depression [6A70-6A7Z] [29]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Thalidomide and Desvenlafaxine. Depression [6A70-6A7Z] [29]
OPC-34712 DMHG57U Moderate Additive CNS depression effects by the combination of Thalidomide and OPC-34712. Depression [6A70-6A7Z] [29]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Thalidomide and Clomipramine. Depression [6A70-6A7Z] [29]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Thalidomide and Doxepin. Depression [6A70-6A7Z] [29]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Thalidomide and Esketamine. Depression [6A70-6A7Z] [29]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [24]
Heroin diacetylmorphine DMDBWHY Moderate Additive CNS depression effects by the combination of Thalidomide and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [28]
Tetrabenazine DMYWQ0O Moderate Additive CNS depression effects by the combination of Thalidomide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [29]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Thalidomide and Deutetrabenazine. Dystonic disorder [8A02] [29]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Thalidomide and Ingrezza. Dystonic disorder [8A02] [29]
Methsuximide DM6L5VO Moderate Additive CNS depression effects by the combination of Thalidomide and Methsuximide. Epilepsy/seizure [8A61-8A6Z] [29]
Cenobamate DM8KLU9 Moderate Additive CNS depression effects by the combination of Thalidomide and Cenobamate. Epilepsy/seizure [8A61-8A6Z] [29]
Stiripentol DMMSDOY Moderate Additive CNS depression effects by the combination of Thalidomide and Stiripentol. Epilepsy/seizure [8A61-8A6Z] [29]
Phenacemide DMOHS9P Moderate Additive CNS depression effects by the combination of Thalidomide and Phenacemide. Epilepsy/seizure [8A61-8A6Z] [28]
Fosphenytoin DMOX3LB Moderate Additive CNS depression effects by the combination of Thalidomide and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [29]
Brivaracetam DMSEPK8 Moderate Additive CNS depression effects by the combination of Thalidomide and Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [29]
Clonazepam DMTO13J Moderate Additive CNS depression effects by the combination of Thalidomide and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [29]
Lacosamide DMVM6QR Moderate Additive CNS depression effects by the combination of Thalidomide and Lacosamide. Epilepsy/seizure [8A61-8A6Z] [29]
Rufinamide DMWE60C Moderate Additive CNS depression effects by the combination of Thalidomide and Rufinamide. Epilepsy/seizure [8A61-8A6Z] [29]
Phenobarbital DMXZOCG Moderate Additive CNS depression effects by the combination of Thalidomide and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [29]
Vigabatrin DMYT0OG Moderate Additive CNS depression effects by the combination of Thalidomide and Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [29]
Cannabidiol DM0659E Moderate Additive CNS depression effects by the combination of Thalidomide and Cannabidiol. Epileptic encephalopathy [8A62] [29]
Diphenhydramine DMKQTBA Moderate Additive CNS depression effects by the combination of Thalidomide and Diphenhydramine. Episodic vestibular syndrome [AB31] [29]
Nadolol DMW6GVL Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Nadolol. Essential hypertension [BA00] [25]
Dantrolene DM1D8XY Moderate Additive CNS depression effects by the combination of Thalidomide and Dantrolene. Fever [MG26] [29]
Sunitinib DMCBJSR Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [25]
Metipranolol DMJMVKI Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Metipranolol. Glaucoma [9C61] [25]
Levobetaxolol DMSREPX Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Levobetaxolol. Glaucoma [9C61] [25]
Levobunolol DMTNFCQ Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Levobunolol. Glaucoma [9C61] [25]
Pilocarpine DMV9ADG Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Pilocarpine. Glaucoma [9C61] [25]
Colchicine DM2POTE Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Colchicine. Gout [FA25] [24]
Carvedilol DMHTEAO Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Carvedilol. Heart failure [BD10-BD1Z] [25]
Digitoxin DMWVIGP Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Digitoxin. Heart failure [BD10-BD1Z] [25]
Telbivudine DMSWUGE Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Telbivudine. Hepatitis virus infection [1E50-1E51] [24]
Procarbazine DMIK367 Major Additive thrombogenic effects by the combination of Thalidomide and Procarbazine. Hodgkin lymphoma [2B30] [26]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [24]
Fostemsavir DM50ILT Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [25]
Saquinavir DMG814N Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [25]
Etravirine DMGV8QU Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Etravirine. Human immunodeficiency virus disease [1C60-1C62] [24]
Lopinavir DMITQS0 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [25]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [25]
Atazanavir DMSYRBX Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Atazanavir. Human immunodeficiency virus disease [1C60-1C62] [25]
Fluvastatin DM4MDJY Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Fluvastatin. Hyper-lipoproteinaemia [5C80] [24]
Rosuvastatin DMMIQ7G Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [24]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Thalidomide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [31]
Penbutolol DM4ES8F Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Penbutolol. Hypertension [BA00-BA04] [25]
Nebivolol DM7F1PA Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Nebivolol. Hypertension [BA00-BA04] [25]
Levamlodipine DM92S6N Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Levamlodipine. Hypertension [BA00-BA04] [25]
Hydralazine DMU8JGH Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Hydralazine. Hypertension [BA00-BA04] [24]
Clevidipine butyrate DMW4M97 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Clevidipine butyrate. Hypertension [BA00-BA04] [25]
Suvorexant DM0E6S3 Moderate Additive CNS depression effects by the combination of Thalidomide and Suvorexant. Insomnia [7A00-7A0Z] [29]
Amobarbital DM0GQ8N Moderate Additive CNS depression effects by the combination of Thalidomide and Amobarbital. Insomnia [7A00-7A0Z] [28]
Tasimelteon DMLOQ1V Moderate Additive CNS depression effects by the combination of Thalidomide and Tasimelteon. Insomnia [7A00-7A0Z] [29]
Paraldehyde DMOC1BX Moderate Additive CNS depression effects by the combination of Thalidomide and Paraldehyde. Insomnia [7A00-7A0Z] [28]
ITI-007 DMUQ1DO Moderate Additive CNS depression effects by the combination of Thalidomide and ITI-007. Insomnia [7A00-7A0Z] [29]
Quazepam DMY4D87 Moderate Additive CNS depression effects by the combination of Thalidomide and Quazepam. Insomnia [7A00-7A0Z] [29]
Estazolam DMZGXUM Moderate Additive CNS depression effects by the combination of Thalidomide and Estazolam. Insomnia [7A00-7A0Z] [29]
Remimazolam DMLVSYX Moderate Additive CNS depression effects by the combination of Thalidomide and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [28]
Nelarabine DMB6VEG Major Additive thrombogenic effects by the combination of Thalidomide and Nelarabine. Leukaemia [2A60-2B33] [26]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Thalidomide and Denosumab. Low bone mass disorder [FB83] [32]
Crizotinib DM4F29C Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Crizotinib. Lung cancer [2C25] [25]
Ceritinib DMB920Z Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Ceritinib. Lung cancer [2C25] [25]
Lurbinectedin DMEFRTZ Major Additive thrombogenic effects by the combination of Thalidomide and Lurbinectedin. Lung cancer [2C25] [26]
Osimertinib DMRJLAT Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Osimertinib. Lung cancer [2C25] [25]
Selpercatinib DMZR15V Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Selpercatinib. Lung cancer [2C25] [25]
Lumefantrine DM29GAD Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lumefantrine. Malaria [1F40-1F45] [25]
Halofantrine DMOMK1V Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Halofantrine. Malaria [1F40-1F45] [25]
Hydroxychloroquine DMSIVND Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Hydroxychloroquine. Malaria [1F40-1F45] [25]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [25]
Calaspargase pegol DMQZBXI Major Additive thrombogenic effects by the combination of Thalidomide and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [30]
Fludarabine DMVRLT7 Major Additive thrombogenic effects by the combination of Thalidomide and Fludarabine. Malignant haematopoietic neoplasm [2B33] [26]
Arsenic trioxide DM61TA4 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [25]
Ponatinib DMYGJQO Major Additive thrombogenic effects by the combination of Thalidomide and Ponatinib. Mature B-cell lymphoma [2A85] [26]
Arry-162 DM1P6FR Major Additive thrombogenic effects by the combination of Thalidomide and Arry-162. Melanoma [2C30] [26]
Vemurafenib DM62UG5 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Vemurafenib. Melanoma [2C30] [25]
LGX818 DMNQXV8 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and LGX818. Melanoma [2C30] [25]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Thalidomide and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [33]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Thalidomide and Lasmiditan. Migraine [8A80] [34]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Thalidomide and Flibanserin. Mood disorder [6A60-6E23] [35]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Thalidomide and Tecfidera. Multiple sclerosis [8A40] [36]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Thalidomide and Siponimod. Multiple sclerosis [8A40] [25]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Thalidomide and Fingolimod. Multiple sclerosis [8A40] [37]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Thalidomide and Ocrelizumab. Multiple sclerosis [8A40] [38]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Thalidomide and Ozanimod. Multiple sclerosis [8A40] [27]
Deflazacort DMV0RNS Major Additive thrombogenic effects by the combination of Thalidomide and Deflazacort. Muscular dystrophy [8C70] [26]
Neostigmine DM6T2J3 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Neostigmine. Myasthenia gravis [8C6Y] [25]
Ambenonium DMOP0BL Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Ambenonium. Myasthenia gravis [8C6Y] [25]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Romidepsin. Mycosis fungoides [2B01] [25]
Vorinostat DMWMPD4 Major Additive thrombogenic effects by the combination of Thalidomide and Vorinostat. Mycosis fungoides [2B01] [26]
Decitabine DMQL8XJ Major Additive thrombogenic effects by the combination of Thalidomide and Decitabine. Myelodysplastic syndrome [2A37] [26]
Nilotinib DM7HXWT Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Nilotinib. Myeloproliferative neoplasm [2A20] [25]
Dasatinib DMJV2EK Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Dasatinib. Myeloproliferative neoplasm [2A20] [25]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Thalidomide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [39]
Phenindamine DMDTC7R Moderate Additive CNS depression effects by the combination of Thalidomide and Phenindamine. Nasopharyngitis [CA00] [28]
Promethazine DM6I5GR Moderate Additive CNS depression effects by the combination of Thalidomide and Promethazine. Nausea/vomiting [MD90] [29]
Cyclizine DM9G7BS Moderate Additive CNS depression effects by the combination of Thalidomide and Cyclizine. Nausea/vomiting [MD90] [28]
Metoclopramide DMFA5MY Moderate Additive CNS depression effects by the combination of Thalidomide and Metoclopramide. Nausea/vomiting [MD90] [29]
E-2007 DMJDYNQ Moderate Additive CNS depression effects by the combination of Thalidomide and E-2007. Neuropathy [8C0Z] [29]
Entrectinib DMMPTLH Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Entrectinib. Non-small cell lung cancer [2C25] [25]
Sibutramine DMFJTDI Moderate Additive CNS depression effects by the combination of Thalidomide and Sibutramine. Obesity [5B80-5B81] [28]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Thalidomide and Levomethadyl Acetate. Opioid use disorder [6C43] [27]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Thalidomide and Lofexidine. Opioid use disorder [6C43] [29]
Rucaparib DM9PVX8 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Rucaparib. Ovarian cancer [2C73] [25]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Thalidomide and Oxymorphone. Pain [MG30-MG3Z] [29]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Thalidomide and Dezocine. Pain [MG30-MG3Z] [28]
Flavoxate DMKV4NL Moderate Additive CNS depression effects by the combination of Thalidomide and Flavoxate. Pain [MG30-MG3Z] [29]
Ziconotide DMSLJP4 Moderate Additive CNS depression effects by the combination of Thalidomide and Ziconotide. Pain [MG30-MG3Z] [29]
Triclabendazole DMPWGBR Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Triclabendazole. Parasitic worm infestation [1F90] [25]
Pergolide DM14MAE Moderate Additive CNS depression effects by the combination of Thalidomide and Pergolide. Parkinsonism [8A00] [29]
Opicapone DM1BKA6 Moderate Additive CNS depression effects by the combination of Thalidomide and Opicapone. Parkinsonism [8A00] [28]
Rasagiline DM3WKQ4 Moderate Additive CNS depression effects by the combination of Thalidomide and Rasagiline. Parkinsonism [8A00] [29]
Levodopa DMN3E57 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Levodopa. Parkinsonism [8A00] [24]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Pimavanserin. Parkinsonism [8A00] [25]
Bromocriptine DMVE3TK Moderate Additive CNS depression effects by the combination of Thalidomide and Bromocriptine. Parkinsonism [8A00] [29]
Orphenadrine DMW542E Moderate Additive CNS depression effects by the combination of Thalidomide and Orphenadrine. Parkinsonism [8A00] [29]
Macimorelin DMQYJIR Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Macimorelin. Pituitary gland disorder [5A60-5A61] [25]
Lefamulin DME6G97 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lefamulin. Pneumonia [CA40] [25]
Degarelix DM3O8QY Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Degarelix. Prostate cancer [2C82] [25]
ABIRATERONE DM8V75C Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and ABIRATERONE. Prostate cancer [2C82] [25]
Enzalutamide DMGL19D Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Enzalutamide. Prostate cancer [2C82] [25]
Relugolix DMK7IWL Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Relugolix. Prostate cancer [2C82] [25]
Estramustine DMWTAOI Major Additive thrombogenic effects by the combination of Thalidomide and Estramustine. Prostate cancer [2C82] [30]
Bicalutamide DMZMSPF Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Bicalutamide. Prostate cancer [2C82] [25]
Terazosin DM3JCVS Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Terazosin. Prostate hyperplasia [GA90] [25]
Levomepromazine DMIKFEL Moderate Additive CNS depression effects by the combination of Thalidomide and Levomepromazine. Psychotic disorder [6A20-6A25] [27]
Axitinib DMGVH6N Major Additive thrombogenic effects by the combination of Thalidomide and Axitinib. Renal cell carcinoma [2C90] [26]
Gatifloxacin DMSL679 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [25]
Neupro DMHEAB1 Moderate Additive CNS depression effects by the combination of Thalidomide and Neupro. Restless legs syndrome [7A80] [29]
Tocilizumab DM7J6OR Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Tocilizumab. Rheumatoid arthritis [FA20] [24]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Thalidomide and Canakinumab. Rheumatoid arthritis [FA20] [40]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Thalidomide and Rilonacept. Rheumatoid arthritis [FA20] [40]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Thalidomide and Golimumab. Rheumatoid arthritis [FA20] [41]
Dexamethasone DMMWZET Major Additive thrombogenic effects by the combination of Thalidomide and Dexamethasone. Rheumatoid arthritis [FA20] [26]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Thalidomide and Leflunomide. Rheumatoid arthritis [FA20] [31]
Quetiapine DM1N62C Moderate Additive CNS depression effects by the combination of Thalidomide and Quetiapine. Schizophrenia [6A20] [29]
Aripiprazole DM3NUMH Moderate Additive CNS depression effects by the combination of Thalidomide and Aripiprazole. Schizophrenia [6A20] [29]
Iloperidone DM6AUFY Moderate Additive CNS depression effects by the combination of Thalidomide and Iloperidone. Schizophrenia [6A20] [29]
Paliperidone DM7NPJS Moderate Additive CNS depression effects by the combination of Thalidomide and Paliperidone. Schizophrenia [6A20] [29]
Molindone DMAH70G Moderate Additive CNS depression effects by the combination of Thalidomide and Molindone. Schizophrenia [6A20] [29]
Thiothixene DMDINC4 Moderate Additive CNS depression effects by the combination of Thalidomide and Thiothixene. Schizophrenia [6A20] [29]
Amisulpride DMSJVAM Moderate Additive CNS depression effects by the combination of Thalidomide and Amisulpride. Schizophrenia [6A20] [29]
Asenapine DMSQZE2 Moderate Additive CNS depression effects by the combination of Thalidomide and Asenapine. Schizophrenia [6A20] [29]
Pimozide DMW83TP Moderate Additive CNS depression effects by the combination of Thalidomide and Pimozide. Schizophrenia [6A20] [29]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Thalidomide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [42]
Ifosfamide DMCT3I8 Major Additive thrombogenic effects by the combination of Thalidomide and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [26]
Docetaxel DMDI269 Major Additive thrombogenic effects by the combination of Thalidomide and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [26]
Trabectedin DMG3Y89 Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [24]
Mitoxantrone DMM39BF Major Additive thrombogenic effects by the combination of Thalidomide and Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [26]
LEE011 DMMX75K Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and LEE011. Solid tumour/cancer [2A00-2F9Z] [25]
Vandetanib DMRICNP Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [25]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [25]
Taxol DMUOT9V Major Additive thrombogenic effects by the combination of Thalidomide and Taxol. Solid tumour/cancer [2A00-2F9Z] [26]
Pitolisant DM8RFNJ Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Pitolisant. Somnolence [MG42] [25]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [25]
Plicamycin DM7C8YV Major Additive thrombogenic effects by the combination of Thalidomide and Plicamycin. Testicular cancer [2C80] [30]
Lenvatinib DMB1IU4 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Lenvatinib. Thyroid cancer [2D10] [25]
Cabozantinib DMIYDT4 Major Additive thrombogenic effects by the combination of Thalidomide and Cabozantinib. Thyroid cancer [2D10] [26]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Thalidomide and Papaverine. Tonus and reflex abnormality [MB47] [43]
Secnidazole DMJ18YL Moderate Increased risk of peripheral neuropathy by the combination of Thalidomide and Secnidazole. Vaginal discharge [MF3A] [24]
Chlorpheniramine DM5URA2 Moderate Additive CNS depression effects by the combination of Thalidomide and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [29]
Trimeprazine DMEMV9D Moderate Additive CNS depression effects by the combination of Thalidomide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [27]
Propafenone DMPIBJK Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Propafenone. Ventricular tachyarrhythmia [BC71] [25]
Flecainide DMSQDLE Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Flecainide. Ventricular tachyarrhythmia [BC71] [25]
Amiodarone DMUTEX3 Moderate Increased risk of ventricular arrhythmias by the combination of Thalidomide and Amiodarone. Ventricular tachyarrhythmia [BC71] [25]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Thalidomide and Valganciclovir. Virus infection [1A24-1D9Z] [25]
⏷ Show the Full List of 215 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Magnesium stearate E00208 11177 lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Thalidomide 100 mg capsule 100 mg Oral Capsule Oral
Thalidomide 150 mg capsule 150 mg Oral Capsule Oral
Thalidomide 200 mg capsule 200 mg Oral Capsule Oral
Thalidomide 50 mg capsule 50 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Thalidomide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7327).
3 ClinicalTrials.gov (NCT04273529) The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia. U.S. National Institutes of Health.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
9 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
10 Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
11 Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.
12 Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
13 Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem Res Toxicol. 2010 Jun 21;23(6):1018-24.
14 Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. J Neurooncol. 2003 Sep;64(3):193-201. doi: 10.1023/a:1025618022921.
15 Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005 Apr 15;105(8):3286-94. doi: 10.1182/blood-2004-06-2101. Epub 2004 Dec 23.
16 Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol. 2005 Aug 10;23(23):5334-46. doi: 10.1200/JCO.2005.03.723. Epub 2005 Jun 6.
17 [Effects of thalidomide on Annexin II gene regulation]. Zhonghua Xue Ye Xue Za Zhi. 2009 Jul;30(7):464-7.
18 Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol. 2005 Aug;43(2):112-9. doi: 10.1016/j.vph.2005.04.003.
19 Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Leukemia. 2005 Aug;19(8):1497-9. doi: 10.1038/sj.leu.2403811.
20 NF-kappaB protects Beh?et's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum. 2005 Jul;52(7):2179-91. doi: 10.1002/art.21145.
21 Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
22 Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology. 2001 May;120(6):1567-8. doi: 10.1053/gast.2001.24495.
23 Immunological consequences of thalidomide treatment in Sj?gren's syndrome. Ann Rheum Dis. 2006 Jan;65(1):112-4. doi: 10.1136/ard.2005.038406.
24 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
25 Cerner Multum, Inc. "Australian Product Information.".
26 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
27 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
29 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
30 Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
31 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
32 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
33 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
34 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
35 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
36 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
37 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
38 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
39 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
40 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
41 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
42 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
43 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]